Anti-SOX10 antibody systems and methods

• US 9,816,997 B2
• Filed: 10/03/2014
• Issued: 11/14/2017
• Est. Priority Date: 10/03/2013
• Status: Active Grant

• Current Assignee: Biocare Medical LLC
• Original Assignee: Biocare Medical LLC
• Inventors: Tacha, David, Qi, Weimin
• Primary Examiner(s): FOSTER, CHRISTINE E
• Application Number:
  US15/026,904
• Publication Number:
  US 20160216269A1
• Time in Patent Office: 1,138 Days
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/3053 Skin, nerves, brain
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 33/57496 involving intracellular compounds

Abstract

The present invention is related to the anti-SOX10 antibodies, kits, cocktails, and use of anti-SOX10 antibodies for detection of cancer.

Claims

1. An antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-120969.

2. A composition comprising the antibody of claim 1 and at least one additional antibody or fragment thereof.

3. The composition of claim 2, wherein the at least one additional antibody or fragment thereof is derived from a different species than the antibody of claim 1.

4. The composition of claim 2, wherein the at least one additional antibody or fragment thereof is derived from a species selected from the group consisting of rabbit, goat, horse, chicken, and human.

5. The composition of claim 2, wherein the at least one additional antibody or fragment thereof binds specifically to a protein selected from the group consisting of Tyrosinase, melanoma antigen recognized by T cells 1 (MART-1), and S100.

6. The composition of claim 2, further comprising a label attached to at least one of the antibody of claim 1 and the at least one additional antibody or fragment thereof.

7. The composition of claim 2, wherein said label is selected from the group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, detection enzymes, horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, chromogens, 3,3′

-diaminobenzidine, 3-amino-9-ethylcarbazole, 5-bromo-4-chloro-3-indolyl phosphate, 3,3′

,5,5′

-tetramethylbenzidine, 5-bromo-4-chloro-3-indolyl-β

-D-glucuronide, and any combination thereof.

8. A method for detecting, in a biological sample, a protein to which the antibody of claim 1 binds;

comprising the steps of contacting the biological sample with the antibody of claim 1 and detecting the presence of the antibody bound to the protein in the biological sample.

9. The method of claim 8, wherein said biological sample comprises lung tissue, bladder tissue, breast tissue, or prostate tissue.

10. The method of claim 8, wherein said biological sample is selected from the group consisting of a normal tissue, neoplastic tissue, bladder tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, prostate tissue, lung tissue, skin tissue, and breast tissue.

11. The method of claim 8, wherein said detecting said presence of the antibody bound to the protein is performed on an automated staining device.

12. The method of claim 8, wherein said detecting said presence of the antibody bound to the protein comprises detecting selected from the group consisting of:

manually detecting, automatically detecting, and image analysis.

13. The method of claim 8, wherein said detecting comprises a method selected from the group consisting of immunohistochemistry (IHC), IHC of formalin-fixed paraffin embedded (FFPE) tissue, IHC of frozen-tissue sections, immunocytochemistry, and ELISA.

14. The method of claim 8, wherein the biological sample comprises tissue;

and wherein the method further comprises the steps of fixing or freezing said tissue, and treating said fixed or frozen tissue to unmask epitopes to Sry-related HMG-Box gene 10 protein (SOX10).